Fig. 5: Patients potentially eligible for checkpoint inhibitors (CPIs). | Modern Pathology

Fig. 5: Patients potentially eligible for checkpoint inhibitors (CPIs).

From: A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases

Fig. 5

By combining PD-L1 IHC and CGP, we found that 39.5% (19,260/48,782) had positivity in at least one CDx biomarker. Of the remaining patients, 17.8% (5267/29,522) were positive for at least one of the exploratory PD-L1 biomarkers. In sum, 50.3% (24,527/48,782) of the total cohort had positivity in at least one CDx or exploratory biomarker.

Back to article page